[HTML][HTML] Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients
V Huber, L Di Guardo, L Lalli, D Giardiello… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Myeloid-derived suppressor cells (MDSC), a cornerstone of cancer-related
immunosuppression, influence response to therapy and disease outcomes in melanoma …
immunosuppression, influence response to therapy and disease outcomes in melanoma …
[HTML][HTML] Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
A Gaißler, J Bochem, J Spreuer, S Ottmann… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background The need for reliable clinical biomarkers to predict which patients with
melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several …
melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several …
[HTML][HTML] Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma
RD Lardone, SB Plaisier, MS Navarrete… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Platform and study differences in prognostic signatures from metastatic melanoma (MM)
gene expression reports often hinder consensus arrival. We performed survival/outcome …
gene expression reports often hinder consensus arrival. We performed survival/outcome …
Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management
Z Liu, H Xu, S Weng, C Guo, Q Dang, Y Zhang… - Cancer Immunology …, 2023 - Springer
Background Although immunotherapy and targeted treatments have dramatically improved
the survival of melanoma patients, the intra-or intertumoral heterogeneity and drug …
the survival of melanoma patients, the intra-or intertumoral heterogeneity and drug …
[HTML][HTML] Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells
JB Freeman, ES Gray, M Millward, R Pearce… - Journal of translational …, 2012 - Springer
Abstract Background Circulating melanoma cells (CMCs) are thought to be valuable in
improving measures of prognosis in melanoma patients and may be a useful marker of …
improving measures of prognosis in melanoma patients and may be a useful marker of …
[HTML][HTML] Effect of immune checkpoint blockade on myeloid-derived suppressor cell populations in patients with melanoma
SH Sun, B Benner, H Savardekar, G Lapurga… - Frontiers in …, 2021 - frontiersin.org
Introduction Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid
cells that inhibit anti-tumor immunity and contribute to immune therapy resistance. MDSC …
cells that inhibit anti-tumor immunity and contribute to immune therapy resistance. MDSC …
[HTML][HTML] Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma
D Klinac, ES Gray, JB Freeman, A Reid, S Bowyer… - BMC cancer, 2014 - Springer
Background New effective treatments for metastatic melanoma greatly improve survival in a
proportion of patients. However biomarkers to identify patients that are more likely to benefit …
proportion of patients. However biomarkers to identify patients that are more likely to benefit …
[HTML][HTML] Machine learning-based construction of immunogenic cell death-related score for improving prognosis and response to immunotherapy in melanoma
G Li, H Zhang, J Zhao, Q Liu, J Jiao, M Yang… - Aging (Albany …, 2023 - ncbi.nlm.nih.gov
Background: Immunogenic cell death (ICD) is a form of regulated cell death (RCD) which
could drive the activation of the innate and adaptive immune responses. In this work, we …
could drive the activation of the innate and adaptive immune responses. In this work, we …
[HTML][HTML] Clinical categorization algorithm (CLICAL) and machine learning approach (SRF-CLICAL) to predict clinical benefit to immunotherapy in metastatic melanoma …
G Madonna, GV Masucci, M Capone, D Mallardo… - Cancers, 2021 - mdpi.com
Simple Summary Immune checkpoint inhibitors have improved the prognosis for patients
with advanced melanoma. Despite the recent success of immunotherapy, many patients still …
with advanced melanoma. Despite the recent success of immunotherapy, many patients still …
Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
A Martens, H Zelba, C Garbe, G Pawelec… - …, 2014 - Taylor & Francis
The percentage of circulating CD14+ CD11b+ HLA-DR−/low myeloid-derived suppressor
cells (MDSCs) inversely correlates with survival among advanced melanoma patients. High …
cells (MDSCs) inversely correlates with survival among advanced melanoma patients. High …